Inhibitor/Activator
| Cat.No. | Name | Information |
|---|---|---|
| M21626 | Cadisegliatin (TTP-399) | Cadisegliatin (TTP-399) is a potential, orally active liver-selective glucokinase (GK) activator. Cadisegliatin has antihyperglycaemic activity. Cadisegliatin can be used for the research of type 2 diabetes. |
| M10305 | AZD1656 | AZD1656 is a potent, selective and orally active glucokinase (GK) activator, with an EC50 of 60 nM. |
| M10047 | Dorzagliatin | Dorzagliatin (HMS-5552, RO-5305552, Sinogliatin) is a glucokinase (GK) activator, which improves glycaemic control and pancreatic β-cell function for type 2 diabetes. |
| M7567 | AM2394 | AM-2394 is a structurally distinct glucokinase activator (GKA). AM-2394 activates glucokinase (GK) with an EC50 of 60 nM. |
| M3562 | LY2608204 | LY2608204 activates glucokinase (GK) with EC50 of 42 nM. |
| M42408 | AZD1092 | AZD1092 is an orally active glucokinase (GK) activator with an EC50 value of 0.03 μM. |
| M31411 | GKM-001 | GKM-001 is a glucokinase (GK) activator that can be used in studies related to type 2 diabetes. |
| M31409 | TMG-123 | TMG-123 is a glucokinase (GK) activator that can be used in studies related to type 2 diabetes. |
| M31408 | PB-201 | PB-201 is a glucokinase activator (GKA) that can be used in studies related to type 2 diabetes. |
| M30576 | MK-0941 free base | MK-0941 free base is an orally active glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes. |
| M28249 | AMG-1694 | AMG-1694 is a potent glucokinase–glucokinase regulatory protein (GK-GKRP) disruptors and promotes the dissociation of the GK-GKRP complex with an IC50 of 7 nM, indirectly increasing GK enzymatic activity. AMG-1694 potently reverses the inhibitory effect of GKRP on GK activity and promotes GK translocation. AMG-1694 normalizes blood glucose levels in several rodent models of diabetes and lowes blood glucose restricted to diabetic and not normoglycaemic animals. |
| M27831 | MK-0941 | MK-0941 is a potent, orally active and allosteric glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 has potential in the treatment of type 2 diabetes. |
| M20373 | WAY-615145 | WAY-615145 is a glucokinase activator. |
| M20368 | WAY-297848 | WAY-297848 is a glucokinase activator. |
| M20087 | WAY-320081 | WAY-320081 is a glucokinase activator |
| M20086 | WAY-320080 | WAY-320080 is a glucokinase activator |
| M14437 | RO-28-1675 | RO-28-1675 is a potent allosteric glucokinase (GK) activator with an EC50 of 54 nM. RO-28-1675 can be used for the research of type 2 diabetes. |
| M7116 | PF 04991532 | PF 04991532 is a potent hepatoselective glucokinase activator. |
| M6751 | GKA 50 | GKA 50 is a glucokinase activator. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
